Medicine at the Crick: Biological therapies in cancer – improving survival outcomes

The session will review the profound opportunities of CAR-T cell therapy, adoptive cellular immunotherapies and checkpoint inhibitor therapy in the management of haematologic and metastatic solid tumours.

These Immunotherapies, by leveraging the patient's immune system, are transforming clinical care, resulting in prolonged survival and even cancer cures in a previously palliative setting. This event will review recent breakthroughs in the field, challenges and opportunities in the translation of scientific findings into the clinic and the promise of leveraging adaptive cellular therapies to tackle cancer clonal evolution for patient benefit.

Speakers include Professor Sergio Quezada and Professor Martin Pule from the UCL Cancer Institute.

'Medicine at the Crick' showcases major advances in biomedical science and raises awareness of the medical implications of major scientific advances.